CTRI/2023/07/055699尚未招募4 期
A Prospective, Interventional, Single Arm, Multi-Centre, Phase 4 Study to Assessthe Safety and Efficacy of Ranibizumab in Participants with Retinopathy of Prematurity.
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •(1) Parent(s) (preferably both if available or per local requirements) or their legally acceptable representative must sign an ICF indicating that they understand the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is also required of children capable of understanding the nature of the study described in Informed Consent Process in Appendix 10.1.3.
- •(2) Male or female preterm infants with gestational age at birth less than or equal to 32 weeks OR birth weight less than or equal to 1500 g.
- •(3) Weight at baseline (day of first injection) greater than or equal to 800 gm.
- •(4) ROP classified according to the International Classification for ROP in at least one eye as: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior ROP.
- •If both eyes are eligible, then both are included. If only one eye is eligible as per above criteria and the fellow eye has ROP but is not eligible, then fellow eye will receive the treatment as per investigator’s discretion. If one eye is eligible and the fellow eye later develops ROP during study, then the fellow eye will receive the treatment as per investigator’s discretion.
排除标准
- •Any potential participant who meets any of the following criteria will be excluded from participating in the study:
- •(1) Known allergies, hypersensitivity, or intolerance to any of the study interventions, or components/excipients thereof (refer to the locally approved package insert of Razumab[1]),, or drug or other allergy (either in the participant or mother) that, in the opinion of the investigator, contraindicates participation in the study.
- •(2) Have ocular structural abnormalities that are assessed by the investigator to have a clinically significant impact on study assessments.
- •(3) Have received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy).
- •(4) Have been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this childs pregnancy).
- •(5) Have active ocular infection in the study eye within 5 days before or on the day of first IMP administration which is judged by the investigator to interfere with the study drug administration.
- •(6) Have a history of hydrocephalus requiring treatment as judged by the investigator.
- •(7) Have a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function.
- •(8) Have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer.
- •(9) Paediatric conditions rendering the infant ineligible for study intervention at baseline as evaluated by a NICU specialist and a study ophthalmologist.
- •(10) Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor life expectancy, pupil not able to be adequately dilated, unable to comply with the visit schedule).
- •NOTE: Investigators should ensure that all study enrolment criteria have been met at screening. If a participants clinical status changes (including any available laboratory results or receipt of additional medical records) after screening but before the first dose of study intervention is given such that the participant no longer meets all eligibility criteria, then the participant should be reevaluated from participation in the study.
研究者
相似试验
招募中
4 期
A Study to Investigate Safety, Efficacy and Immunogenicity of Denosumab in Patients with Bone Metastases from Advanced MalignanciesCTRI/2023/01/049158Intas Pharmaceuticals Limited
进行中（未招募）
1 期
Evaluation of Toujeo insulin in type 2 diabetes patients inadequately control with their basal insulin treatmentEUCTR2015-002416-33-FRsanofi-aventis France350
招募中
Unknown
A clinical study to evaluate safety and performance of absorbable, gelatin-based hemostat in patients undergoing different types of surgeries.CTRI/2024/01/061742Aegis Lifesciences Pvt. Ltd.
Unknown
2 期
A clinical trial to evaluate efficacy and safety of R-TPR-004 in patients with acute ischemic strokeCTRI/2013/04/003590Reliance Life Sciences Pvt Ltd40
尚未招募
Unknown
Study to evaluate safety and efficacy of TAVI -Transcatheter Aortic Valve (Crea Aortic Valve)CTRI/2024/01/061426Onecrea Medical India